Free Papers

Efficacy of Accelerated Corneal Collagen Crosslinking in Pediatric and Adult Keratoconus Patients

Free Paper Details

First Author: Ö.Özer TURKEY

Co Author(s):    L. Göbel   Ö. Dursun   M. Vatansever   E. Dinç   U. Adıgüzel        

Abstract Details

Purpose:

We aimed to evaluate the efficacy of accelerated corneal collagen cross linking (CXL) treatment to stop progression of disease in patients with progressive keratoconus disease in different age groups.

Setting:

: This study was conducted at Department of Ophthalmology, Faculty of Medicine, Mersin University (Mersin, Turkey).

Methods:

Seventy-four eyes of 55 patients treated with accelerated CXL (9 mW/cm2, 10 minutes) for progressive keratoconus were included in this study. The best corrected visual acuity, autorefractometry measurements and corneal topographic examinations of all patients were performed before and after CXL. All data of patients were divided into 2 groups as younger than 18 years old (25 eyes, 17 patients) and those 18 years and older (49 eyes, 38 patients).

Results:

In the group 1, the mean age was 17.76±1.67 years, and the mean follow-up period after CXL was 18.64 ± 6.47 months. The mean age was 29.57±6.74 years, and the mean follow-up period after CXL was 21.43 ± 5.09 months in the group 2. There were significantly decrease in keratometric values (for both groups and all parameters, p <0.0001), significantly increase in the best corrected visual acuity (BCVA) values (p = 0.04 in Group 1, p <0.0001 in Group 2); aberrometry values and corneal curvature indices significantly decreased in both groups.

Conclusions:

Corneal collagen crosslinking treatment is a safe method that stop progression of disease in pediatric and adult keratoconus patients.

Financial Disclosure:

-